MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$318,521
Unit: Dollar
Positive Cash Flow Breakdown
Financing costs
Net income (loss) and comprehens...
Amortization of debt discount an...
Others
Negative Cash Flow Breakdown
Change in fair value of derivati...
Gain on extinguishment of accoun...
Increase (decrease) in accounts ...
Increase in accounts payable and...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Net income (loss) and comprehensive income (loss)
765,889
-3,601,623
-483,447
-1,742,691
Amortization
-
-
-
0
Stock-based compensation
0
0
0
108,399
Financing costs
-
2,572,655
507,368
-
Allowance for research and development rebate due
0
0
0
-
Financing costs
3,080,023
-
-
-
Gain on sale of product candidates and related assets
-
-
-
0
Allowance for research and development rebate due from australian government
-
-
-
22,625
Change in fair value of derivative liability
1,505,581
-424,348
422,419
-
Impairment of investment in preferred stock of oragenics, inc
-
-
-
0
Amortization of debt discount and closing costs
392,672
289,190
39,601
50,965
Loss from change in fair value of oragenics, inc. common stock
0
0
0
-459,417
Financing costs paid with issuance of common stock
3,500
0
1,750
0
Gain on extinguishment of accounts payable
85,369
-
-
-
(increase) in prepaid expenses and other current assets
-29,004
-13,059
87,397
-6,990
Decrease in research and development rebate due from australian government
-
-
-
0
Increase (decrease) in accounts payable and accrued wages
-50,174
-68,563
73,285
228,379
Increase in accounts payable and accrued wages, officers
-2,387
-33,747
32,308
320,838
Increase in accrued interest
133,925
120,422
54,953
197,686
Net cash used in operating activities
-318,521
-284,259
-283,998
-347,392
Cash proceeds from sale of assets
-
-
-
0
Cash proceeds from sale of oragenics, inc. common stock, net of commission and fees
-
-
-
69,787
Net cash provided by investing activities
-
-
-
69,787
Proceeds from notes payable
0
875,000
290,500
300,000
Principal payments made on notes payable
-
-
-
0
Proceeds from equity financing
-
-
-
0
Deferred closing costs
-
-
-
5,690
Net cash provided by financing activities
0
875,000
290,500
294,310
Increase in cash and cash equivalents
-318,521
590,741
6,502
16,705
Beginning of period
25,586
25,586
19,084
2,379
End of period
297,806
616,327
25,586
19,084
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Increase in cash and cash
equivalents
-$318,521
Financing costs
$3,080,023
Net income (loss)
and comprehensive...
$765,889
Amortization of debt discount
and closing costs
$392,672
Increase in accrued
interest
$133,925
(increase) in prepaid
expenses and other...
-$29,004
Financing costs paid with
issuance of common stock
$3,500
Net cash used in
operating activities
-$318,521
Canceled cashflow
$4,405,013
something is missing
-$3,080,023
Change in fair value of
derivative liability
$1,505,581
Gain on
extinguishment of accounts...
$85,369
Increase (decrease) in
accounts payable and...
-$50,174
Increase in accounts
payable and accrued...
-$2,387
Buy us a coffee
Odyssey Health, Inc. (ODYY)
Odyssey Health, Inc. (ODYY)